Oridonin
HSP70 inhibitor / A potent, covalent inhibitor of the NLRP3 inflammasome with anti-inflammatory activity in various mouse models.1 Inhibits vascular inflammation in vivo.2 Inhibits aberrant AKT activation in human breast cancer cells with hyperactivated PI3K/AKT signaling.3 Inhibits migration, invasion and adhesion of melanoma cells.4 Induces apoptosis in osteosarcoma cells by multiple pathways.5
Biochemicals & reagents
28957-04-2
Isodonol
1) He et al. (2018), Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity; Nat. Commun., 9 2550 2) Huang et al. (2018), Oridonin inhibits vascular inflammation by blocking NF-kB and MAPK activation; Eur. J. Pharmacol., 826 133 3) Sun et al. (2018), Oridonin inhibits aberrant AKT activation in breast cancer; Oncotarget, 9 23878 4) Li et al. (2018), Oridonin inhibits migration, invasion, adhesion and TGF-ß1-induced epithelial-mesenchymal transition of melanoma cells by inhibiting the activity of PI3K/Akt/GSK-3ß signaling athway; Oncol. Lett., 15 1362 5) Lu et al. (2018), Oridonin exerts anticancer effect on osteosarcoma by activating PPAR? and inhbiting Nrf2 pathway; Cell Death Dis., 9 15
-20°C
TARGET: HSP (Heat shock protein); Inflammasome -- PATHWAY: Fatty acid metabolism; Autophagy -- RESEARCH AREA: Neuroscience; Ubiquitin/Proteasome; Cell death; Cellular stress -- DISEASE AREA: Cancer; InflammationNeurodegeneration; Diabetes